Literature DB >> 3801760

Naloxone inhibits arrhythmias induced by coronary artery occlusion and reperfusion in anaesthetized dogs.

X D Huang, A Y Lee, T M Wong, C Y Zhan, Y Y Zhao.   

Abstract

The intravenous administration of naloxone 2 min before coronary artery occlusion in anaesthetized dogs reduced the incidence and severity of cardiac arrhythmias during coronary occlusion (20 min) and reperfusion (120 min) in a dose-related manner. It also reduced the mortality. At a dose of 1 mg kg-1 (the maximum dose used in this study) naloxone abolished the appearance of the life threatening ventricular fibrillation (VF) and ventricular tachycardia (VT) and as a consequence all dogs in this group survived. The results suggest a possible involvement of endogenous opioid peptides in arrhythmogenesis during coronary occlusion and reperfusion in the dog.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3801760      PMCID: PMC1916560          DOI: 10.1111/j.1476-5381.1986.tb10186.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  4 in total

1.  Arrhythmias and cellular electrophysiological changes during myocardial "ischaemia" and reperfusion.

Authors:  W J Penny; D J Sheridan
Journal:  Cardiovasc Res       Date:  1983-06       Impact factor: 10.787

2.  Naloxone inhibits early arrhythmias resulting from acute coronary ligation.

Authors:  O Fagbemi; I Leprán; J R Parratt; L Szekeres
Journal:  Br J Pharmacol       Date:  1982-08       Impact factor: 8.739

3.  Antiarrhythmic evaluation of naloxone against acute coronary occlusion-induced arrhythmias in pigs.

Authors:  J L Bergey; M E Beil
Journal:  Eur J Pharmacol       Date:  1983-06-17       Impact factor: 4.432

4.  Anti-arrhythmic effects of prazosin and propranolol during coronary artery occlusion and re-perfusion in dogs and pigs.

Authors:  B G Benfey; M S Elfellah; R I Ogilvie; D R Varma
Journal:  Br J Pharmacol       Date:  1984-07       Impact factor: 8.739

  4 in total
  5 in total

1.  Failure to reproduce the in vitro cardiac electrophysiological effects of naloxone in humans.

Authors:  K G Oldroyd; A C Rankin; C E Gray; K Harvey; W Borland; A P Rae; S M Cobbe
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

2.  The antiarrhythmic and cardiac electrophysiological effects of buprenorphine.

Authors:  G Boachie-Ansah; R Sitsapesan; K A Kane; J R Parratt
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

3.  Stereospecific antiarrhythmic effects of naloxone against myocardial ischaemia and reperfusion in the dog.

Authors:  A Y Lee
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

4.  Anti-arrhythmic activities of opioid agonists and antagonists and their stereoisomers.

Authors:  Y Sarne; A Flitstein; E Oppenheimer
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

Review 5.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.